Drug Profile
SCB 340
Alternative Names: SCB-340Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Clover Biopharmaceuticals
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action OX40 ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in China
- 28 Dec 2017 Clover Biopharmaceuticals in-licenses Trimer-Tag© technology from GenHunter Corporation worldwide (Clover Biopharmaceuticals website, December 2017)
- 28 Dec 2017 GenHunter Corporation has patent protection for Trimer-Tag© technology in USA, Europe, Japan and China (GenHunter Corporation website, December 2017)